Lemon_tm
- Karyopharm Therapeutics (KPTI) is down ~69% in after-hours trading after reporting that Xpovio (selinexor) missed its primary goal in a phase 3 trial for endometrial cancer.
- There was no significant difference in progression-free survival between patients with TP53 wild-type advanced
